Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union-Reference-Cited by-同舟云学术

Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union

Published:2024-04 Issue:13 Volume:20 Page:821-832
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Wyrwicz Lucjan¹^ORCID,Rodríguez Sánchez César A²^ORCID,Sánchez-Rovira Pedro³^ORCID,Lewis Sandra⁴^ORCID,Sandschafer Darcie⁴^ORCID,San Tevy⁵

Affiliation:

1. Department of Oncology & Radiotherapy, Maria Sklodowska Curie National Cancer Research Institute, Warsaw, Poland

2. Department of Medical Oncology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

3. Department of Oncology, University Hospital of Jaén, Jaén, Spain

4. Global Medical Affairs, Amgen Inc., Thousand Oaks, CA91320, USA

5. Centre Oncologie et Radiothérapie, Chambray-lès-Tours, Centre-Val de Loire, France

Funder

Amgen

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2023-0421

Reference38 articles.

1. American Cancer Society . Breast Cancer HER2 Status (2022). www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html (Accessed 21February2023).

2. National Institutes of Health . Cancer Stat Facts: Female Breast Cancer Subtypes. https://seer.cancer.gov/statfacts/html/breast-subtypes.html (Accessed 21February2023).

3. Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer

4. US Food and Drug Administration . Herceptin Prescribing Information (2010). www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf (Accessed 21February2023).

5. European Medicines Agency . Herceptin Summary of Product Characteristics (2010). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf (Accessed 21February2023).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab;Reactions Weekly;2024-07-27